Cidara Therapeutics Inc
CDTX62.715USD
-0.185-0.29%
Horário de mercado （ET）Cotações atrasadas em 15 min
765.70MValor de mercado
PerdaP/L TTM
Mais detalhes de Cidara Therapeutics Inc Empresa
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Informações da empresa
Código da empresaCDTX
Nome da EmpresaCidara Therapeutics Inc
Data de listagemApr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
Número de funcionários38
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 15
Endereço6310 Nancy Ridge Dr Ste 101
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121-3209
Telefone18587526170
Sitehttps://www.cidara.com/
Código da empresaCDTX
Data de listagemApr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Ritchie
Mr. Brian Ritchie
Investor Relations
Investor Relations
--
--
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
--
--
Mr. Shane Ward
Mr. Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Chief Operating Officer, Chief Legal Officer, Company Secretary
--
--
Dr. Josh Resnick, M.D., J.D.
Dr. Josh Resnick, M.D., J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Investidores
Investidores
Proporção
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Tipos de investidores
Investidores
Proporção
Venture Capital
29.07%
Hedge Fund
24.64%
Investment Advisor
15.03%
Investment Advisor/Hedge Fund
4.77%
Individual Investor
1.12%
Research Firm
0.52%
Pension Fund
0.12%
Other
24.73%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
130
15.18M
75.27%
+7.25M
2025Q1
124
10.47M
53.54%
+2.71M
2024Q4
122
7.70M
70.35%
+1.07M
2024Q3
109
4.49M
61.04%
+771.77K
2024Q2
109
1.90M
39.70%
+56.88K
2024Q1
108
1.55M
384.06%
-209.94K
2023Q4
111
1.70M
37.69%
-299.58K
2023Q3
119
1.90M
42.77%
-451.34K
2023Q2
126
1.95M
43.98%
-451.51K
2023Q1
153
2.02M
47.21%
-214.92K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
3.37M
16.69%
+2.27M
+207.97%
Jun 26, 2025
Commodore Capital LP
1.18M
5.83%
+1.18M
--
Jun 25, 2025
VR Adviser, LLC
1.05M
5.21%
+285.80K
+37.32%
Mar 31, 2025
TCG Crossover Management, LLC
1.01M
4.99%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
999.41K
4.96%
+885.56K
+777.80%
Apr 09, 2025
Adage Capital Management, L.P.
990.00K
4.91%
+620.05K
+167.60%
Mar 31, 2025
BVF Partners L.P.
924.64K
4.59%
-168.15K
-15.39%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
703.08K
3.49%
--
--
Mar 31, 2025
Canaan Partners
703.08K
3.49%
+703.08K
--
Jul 19, 2024
Vivo Capital, LLC
684.28K
3.39%
+13.68K
+2.04%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Dorsey Wright SmallCap Momentum ETF
0.78%
iShares Micro-Cap ETF
0.15%
Avantis US Small Cap Equity ETF
0.05%
iShares Russell 2000 Value ETF
0.05%
Proshares Ultra Russell 2000
0.03%
ProShares UltraPro Russell2000
0.03%
Global X Russell 2000 ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Ver Mais
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.78%
iShares Micro-Cap ETF
Proporção0.15%
Avantis US Small Cap Equity ETF
Proporção0.05%
iShares Russell 2000 Value ETF
Proporção0.05%
Proshares Ultra Russell 2000
Proporção0.03%
ProShares UltraPro Russell2000
Proporção0.03%
Global X Russell 2000 ETF
Proporção0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.03%
ProShares Hedge Replication ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Data
Tipo
Proporção
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
